Business UpdateJul 1, 2026, 09:01 AM
Creative Medical Provides Mid-Year Update on Clinical Programs
AI Summary
Creative Medical Technology Holdings, Inc. provided a mid-year update, highlighting significant progress across its clinical and biodefense programs. The company's lead asset, Olastrocel (CELZ-201), received WHO approval for its name and showed positive interim data in chronic lower back pain, with an FDA-cleared trial expansion. Its Ultrasome™ osteoarthritis program reported breakthrough pilot results, and the CELZ-Biodefense platform advanced with regulatory approval for Project PHOENIX. Creative Medical reiterated its commitment to disciplined capital allocation and pursuing non-dilutive funding opportunities.
Key Highlights
- Olastrocel (CELZ-201) received WHO approval for its International Non-Proprietary Name, marking a global naming milestone.
- Interim 180-day data from the ADAPT trial for Olastrocel showed statistically significant improvements in chronic lower back pain.
- FDA cleared an expansion of the ADAPT trial for Olastrocel, with the new cohort already over 85% enrolled.
- Ultrasome™ pilot results for osteoarthritis showed 93% of patients with clinically meaningful improvements in mobility and pain.
- CELZ-Biodefense Project PHOENIX received regulatory approval and is scaling to 1,000 veterans for data collection.
- Company emphasizes disciplined capital allocation, prioritizing non-dilutive and strategic funding sources.
Price Impact
More from CELZ